Reviewing PetMed Express (PETS) & Valeant Pharmaceuticals …

PetMed Express (NASDAQ: PETS) and Valeant Pharmaceuticals International (NYSE:VRX) are both retail/wholesale companies, though that is a improved investment? We will examination a dual businesses formed on a strength of their dividends, risk, earnings, profitabiliy, institutional ownership, gratefulness and researcher recommendations.

Insider Institutional Ownership

78.3% of PetMed Express shares are hold by institutional investors. Comparatively, 50.4% of Valeant Pharmaceuticals International shares are hold by institutional investors. 4.7% of PetMed Express shares are hold by association insiders. Comparatively, 5.9% of Valeant Pharmaceuticals International shares are hold by association insiders. Strong institutional tenure is an denote that sidestep funds, endowments and vast income managers trust a association is staid for long-term growth.

Profitability

This list compares PetMed Express and Valeant Pharmaceuticals International’s net margins, lapse on equity and lapse on assets.

Earnings and Valuation

This list compares PetMed Express and Valeant Pharmaceuticals International’s revenue, gain per share and valuation.

Valeant Pharmaceuticals International has aloft income and gain than PetMed Express. Valeant Pharmaceuticals International is trade during a reduce price-to-earnings ratio than PetMed Express, indicating that it is now a some-more affordable of a dual stocks.

Analyst Recommendations

This is a outline of stream recommendations and cost targets for PetMed Express and Valeant Pharmaceuticals International, as supposing by MarketBeat.

PetMed Express now has a accord cost aim of $13.00, indicating a intensity downside of 66.03%. Valeant Pharmaceuticals International has a accord cost aim of $18.26, indicating a intensity upside of 44.26%. Given Valeant Pharmaceuticals International’s stronger accord rating and aloft illusive upside, analysts seemingly trust Valeant Pharmaceuticals International is some-more auspicious than PetMed Express.

Risk Volatility

PetMed Express has a beta of 0.97, suggesting that a batch cost is 3% reduction flighty than a SP 500. Comparatively, Valeant Pharmaceuticals International has a beta of -0.34, suggesting that a batch cost is 134% reduction flighty than a SP 500.

Dividends

PetMed Express pays an annual division of $0.80 per share and has a division produce of 2.1%. Valeant Pharmaceuticals International does not compensate a dividend. PetMed Express pays out 68.4% of a gain in a form of a dividend.

About PetMed Express

PetMed Express, Inc. (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets remedy and non-prescription pet medications, and other health products for dogs and cats, approach to a consumer. It offers a preference of products for dogs and cats. Its product line contains approximately 3,000 batch gripping units (SKUS) of pet medications, health products and supplies. Its products embody brands of medication, such as Frontline Plus, K9 Advantix II, Advantage II, Heartgard Plus, Sentinel, Revolution and Rimadyl. It also offers additional pet reserve for sale on a Website, that are dump shipped to a business by third parties. These pet reserve embody food, beds, crates, stairs, strollers and other pet supplies. Its products enclosed Non-Prescription Medications (Over a Counter (OTC)) and supplies, and Prescription Medications (Rx). Its business are located in California, Florida, Texas, New York, Virginia and Georgia, among others.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc. is a curative and medical device company. The Company is intent in building and selling a operation of branded, general and branded general pharmaceuticals, over-the-counter (OTC) products, and medical inclination (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates by dual segments: Developed markets and Emerging markets. In a Developed Markets segment, it focuses on a areas of dermatology, neurology, gastrointestinal disorders, and eye health healing classes. In a Emerging Markets segment, it focuses on essentially on branded generics, OTC products and medical devices. Its curative products embody Xifaxan, Solodyn and Glumetza. Its OTC products embody PreserVision, Biotrue and Boston. Its other general products embody Latanoprost and Metronidazole. Its ophthalmic surgical products embody intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.

Receive News Ratings for PetMed Express Inc. Daily – Enter your email residence next to accept a obvious daily outline of a latest news and analysts’ ratings for PetMed Express Inc. and associated companies with MarketBeat.com’s FREE daily email newsletter.

You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.
Leave a Reply

You must be logged in to post a comment.

  • RSS
  • Facebook
  • Google+
  • Twitter
Read previous post:
Side effects of too most fish oil for dogs

Albany comes up short in semifinal After a pitching battle that lasted eight innings, the Muenster Hornets scored a walk-off...

Close